medigraphic.com
ISSN 2007-6053 (Print)
Órgano oficial de difusión de los Hospitales Regionales de Alta Especialidad (HRAE)

2011, Number 1

<< Back Next >>

Evid Med Invest Salud 2011; 4 (1)

Premalignant lesions in gastric mucosa and its relation to Helicobacter pylori in gastric biopsies

Tafoya-Ramírez F, Günther J, Mijangos-Cruz R, Velásquez-Paz A

Language: Spanish
References: 24
Page: 7-9
PDF size: 169.72 Kb.


ABSTRACT

Introduction: Over the half of the world population is infected by Helicobacter pylori (H. pylori). It was demonstrated its presence in all ages and around the world. H. pylori is detected in 10% to 15% of patients with peptic ulcer and in 3% of those with gastric cancer.
Methods: We performed a retrospective descriptive study in patients with a gastrointestinal diagnosis and gastric mucosa biopsy. The variables analyzed were age, gender, position of the injury, the staging of gastritis by Sydney classification and the presence of intestinal metaplasia.
Results: We studied 609 patients; mean age was 40.5 ± 10.6 (standard deviation) with a range of 21-85 years. Approximately 61% of patients were positive for H. pylori. We found a statistically significant association between positive and negative patients for H. pylori and the type of lesions with p ‹0.001 (χ2> = 10.23). Almost 90% of gastric lesions are located in pyloric antrum.
Discussion: Our results back up that H. pylori could be acting like initiator for gastric lesions, starting with chronic gastritis and ending possibly with gastric cancer. Interesting that we detected 90% of injuries in pyloric antrum, according with H. pylori infection progress but not with other studies results.


REFERENCES

  1. Marshall, BJ. History of the discovery of C. pylori. En: Campylobacter Pylori in Gastritis and Peptic Ulcer Disease, Blaser, MJ (Eds), Igaku-Shoin, New York 1989. pag.7.

  2. Marshall BJ, Warr en JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1:1311.

  3. Go MF. Natural history and epidemiology of Helicobacter pylori infection. Aliment Pharm acol Ther 2002; 16 (suppl. 1): 3-15.

  4. Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 1995; 9 Supl 2:33.

  5. Torres J, Leal-Herrera Y, Perez-Perez G, et al. A community-based seroepidemiologic study of Helicobacter pylori infection in Mexico. J Infect Dis 1998; 178:1089.

  6. Suerbaum S, Michetti P. Helicobacter pylori Infection. N Engl J Med 2002; 347: 1175-86.

  7. Rivas F, Hernández F. Helicobacter pylori: factores de virulencia, patología y diagnóstico. Rev Biomed 2000; 11: 187-205

  8. Gerhard M, Lehn N, Neumayer N, Boren T, Rad R, Schepp W, et al. Clinical relevance of the Helicobacter pylori gene for bloodgr oup antigen-binding adhesion. Proc Natl Acad Sci 1999; 96: 12778-83.

  9. Torres J, Lopez L, Lazcano E, Camorlinga M, Flores L, Muñoz O. Trends in Helicobacter pylori Infection and Gastric Cancer in Mexico. Cancer Epidemiol Biomarkers Prev 2005; 14 (8): 1874-1877.

  10. Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994; 61:177.

  11. Morson BC, Sobin LH, Grundmann E, Johansen A, Nagayo T, Serck-Hanssen A. Precancerous conditions and epithelial dysplasia in the stomach. J Clic Pathol 1980; 33 (8): 711-21.

  12. Valle J, Gisbert JP. Helicobacter pylori infection and precancerous lesions of the stomach. Hepatogastroenterology. 2001; 48 (42): 1548-51.

  13. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people wi th CagA positive or CagA negative Helicobacter pylori infection. Gut 1997; 40: 297-301.

  14. Paull G, Yardley JH. Pathology of C pylori-associated gastric and esophageal lesions. En: Campylobacter Pylori in Gastritis and Peptic Ulcer Disease, Blaser, MJ (Eds), Igaku-Shoin, New York 1989. p.73.

  15. Graham DY , Opekun A, Lew GM, et al. Helicobacter pylori-associated exagg erated gastrin release in duodenal ulcer patients. The effect of bombesin infusion and urea ingestion. Gastroenterology 1991; 100: 1571.

  16. Väänänen H, Vauhkonen M, Helske T, et al. Non-endoscopic diagnosis of atrophic gastritis wi th a blood test. Corr elation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003; 15: 885.

  17. Gutierr ez O, Kim JG, Akamatsu T, et al. Geogr aphic differences in the distribution of intestinal metaplasia in duodenal ulcer patients. Am J Gastroenterol 2001; 96: 666.

  18. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process- -First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735.

  19. Matysiak-Budnik T, Megr aud F. Helicobacter pylori infection and gastric cancer. Eur J Cancer, 2006; 42 (6): 708-16.

  20. MacDonald W.C. and Owen D.A. Chronic atrophic gastritis, intestinal metaplasia of the stomach and partial gastrectomy. En Eastwood G.L. (ed.). Premalignant Conditions of the Gastrointestinal Tract. New York, Elsevier, 1991, p.145

  21. Necchi V, Candusso ME, Tava F, Luinetti O, Ventura U, Fiocca R et al. Intracellular, intercellular, and stromal invasion of gastric mucosa, preneoplastic lesions, and cancer by Helicobacter pylori. Gastroenterology 2007; 132 (3): 1009-1023.

  22. Haziri A, Juniku-Shkololli A, Gashi Z, Berisha D, Haziri A. Helicobacter Pylori Infection And Precancerous Lesions of The Stomach. Med Arh 2010; 64 (4): 248-9.

  23. Oñate-Ocaña LF. Gastric Cancer in Mexico. Gastric cancer 2001; 4: 162-164.

  24. Carillo L. Infección por Helicobacter pylori y cáncer gástrico en México. Un reto para la prevención y el control poblacional, Rev Gastroenterología. Méx 1997; 62 (1): 22-28.




2020     |     www.medigraphic.com